ECDC regularly assesses new evidence on variants detected through epidemic intelligence, rules-based genomic variant screening or other scientific sources.
Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
The objective of this review was to investigate the efficacy, effectiveness and safety of HPV vaccination in women undergoing conisation compared with those not receiving a HPV vaccination.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.